Abiopharma

Withdraw - Cash Dividend/ Distribution :: Mandatory

General Announcement: ANNOUNCEMENT ON THE EVALUATION REPORT ON THE 2024 ACTION PLAN AND ON THE 2025 ACTION PLAN

FDA approve MEROPENEM

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve CEFAZOLIN SODIUM

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve TOPIRAMATE

FDA approve QUINIDINE SULFATE

FDA approve MEROPENEM

FDA approve TOLTERODINE TARTRATE

FDA approve FENOFIBRATE

FDA approve CLORAZEPATE DIPOTASSIUM

FDA approve NALOXONE HYDROCHLORIDE

FDA approve HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm